|
|
|
By Ajaz S. Hussain, Ph.D., independent pharmaceutical regulatory science expert | Pharmaceutical sovereignty is no longer a theoretical concern. Sovereignty in this context does not imply isolation, but rather strategic resilience: building robust national and regional capabilities that ensure security while enabling global collaboration. | |
|
|
|
| Viral Vector Manufacturing: A Case For Adherent Cell Culture | Q&A | By Junwei Sun, Dr. Lucia Fernandez, and Matthew Ercolino, VintaBio | Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development. |
|
|
| A Focus On Cell Therapy: CAR-T, CAR-NK, And Beyond | Article | By Tae Whan Kim, GC Cell | As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology. |
|
|
| Analytical Considerations For mRNA-Based Therapies | Article | By Mark Rogers, Ph.D., SGS | Uncover why leveraging strong scientific expertise and comprehensive testing techniques will be vital in expediting development and upholding the integrity of these life-saving treatments. |
|
|
|
| Lentiviral Vector Platform: Right The First Time | Article | By Mercedes Segura, Dawn Maier, and Bojiao Yin, ElevateBio | Leveraging the right LVV manufacturing platform can accelerate timelines, better manage costs, and transform product development and potential for clinical success so that therapies reach patients in need. |
|
|
| Propelling Gene Therapies From Lab To Clinic | Article | By Lan Ly, Ph.D., FUJIFILM Diosynth Biotechnologies | Many companies are turning to CDMOs to optimize biomanufacturing processes and address the growing list of complications on the path to commercialization. |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
